GRPEL2P3

Across TCGA pan-cancer cohorts, GRPEL2P3 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated GRPEL2P3 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GRPEL2P3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated GRPEL2P3 expression acts as an unfavorable survival marker.

LIHC, READ, and LUSC are the cancer types where GRPEL2P3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.163	0.786	<.001	45	view →
READ	OS	Tertile	III,IV	0.289	0.901	<.001	45	view →
LUSC	OS	Tertile	III,IV	0.215	0.580	.010	36	view →
LUAD	OS	Tertile	All	0.310	0.834	.002	27	view →
UCS	OS	Tertile	All	0.185	0.686	.034	18	view →
SKCM	DFS	Tertile	III,IV	0.015	0.648	<.001	9	view →
PCPG	DFS	Tertile	All	0.161	0.819	.004	9	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GRPEL2P3–LIHC (OS)

Open the LIHC breakdown →